US · Technology · Scientific & Technical Instruments
EPS came in at 0.02 against a street estimate of 0.05 — a miss of 60.0%.
Analysts rate Sono-Tek Corp a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $8.50.
CONFIDENT Sono-Tek delivered first-half growth, margin expansion and stronger operating profit, led by medical demand. Management reiterated flat-to-modest FY2027 revenue growth while record orders improve FY2028 visibility. Q2 FY27 The call mentioned European and China-based customers but did not provide regional revenue percentages or totals. Analysts focused on integrated production-line orders, engineering capacity and medical-device expansion. Management emphasized recurring follow-on orders, potential team expansion and broader implantable-device opportunities. 2026-10-14…
Full summary in the app.
| Fund | Stake |
|---|---|
| Vanguard Capital Management, LLC | 2.37% |
| Geode Capital Management, LLC | 0.95% |
| Renaissance Technologies Corp | 0.73% |
| M&T Bank Corp | 0.51% |
| Morgan Stanley - Brokerage Accounts | 0.44% |
| Vanguard Fiduciary Trust Co | 0.43% |
| Stifel Financial Corp | 0.38% |
| Bard Associates Inc | 0.36% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sono-Tek Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.